Dyne Therapeutics (DYN) News Today $17.08 +0.70 (+4.27%) Closing price 04:00 PM EasternExtended Trading$16.80 -0.27 (-1.61%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Aberdeen Group plc Grows Position in Dyne Therapeutics, Inc. $DYNOctober 17 at 3:32 AM | marketbeat.comDyne’s Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One YearOctober 16, 2025 | msn.comQ3 Earnings Estimate for DYN Issued By Lifesci CapitalOctober 16, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Upgraded at Lifesci CapitalOctober 15, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Cut to "Market Perform" at OppenheimerOctober 13, 2025 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down Following Analyst DowngradeOctober 12, 2025 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down After Analyst DowngradeOctober 11, 2025 | marketbeat.comOppenheimer Reiterates Market Perform Rating for Dyne Therapeutics (NASDAQ:DYN)October 11, 2025 | marketbeat.comOppenheimer Downgrades Dyne Therapeutics (DYN)October 11, 2025 | msn.comDyne Therapeutics (DYN) Receives a Buy from Morgan StanleyOctober 10, 2025 | theglobeandmail.comDyne Therapeutics downgraded to Perform from Outperform at OppenheimerOctober 10, 2025 | msn.comDyne Therapeutics downgraded to Perform at Oppenheimer following additional dataOctober 10, 2025 | msn.comDyne Therapeutics (DYN) Is Up 17.0% After Positive One-Year ACHIEVE Trial Data for Z-Basivarsen – Has The Bull Case Changed?October 10, 2025 | finance.yahoo.comWeiss Ratings Reaffirms Sell (D-) Rating for Dyne Therapeutics (NASDAQ:DYN)October 9, 2025 | marketbeat.comStocks With Rising Relative Price Strength: Dyne TherapeuticsOctober 8, 2025 | msn.comDyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026October 8, 2025 | seekingalpha.comDyne announces additional one-year data from ACHIEVE studyOctober 7, 2025 | msn.comDyne Therapeutics (NASDAQ:DYN) Trading Up 10.8% - Here's WhyOctober 7, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Down 4.7% - Here's WhyOctober 6, 2025 | marketbeat.comDyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic ...October 6, 2025 | markets.businessinsider.comDyne Therapeutics Reports Significant One-Year Clinical Data for Zeleciment Basivarsen in Patients with Myotonic Dystrophy Type 1October 6, 2025 | quiverquant.comQDyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)October 6, 2025 | globenewswire.comDyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial DataOctober 4, 2025 | finance.yahoo.com10 Best Stocks to Buy Under $20October 4, 2025 | insidermonkey.comDyne Therapeutics' Valuation Leaves No Room For ErrorOctober 3, 2025 | seekingalpha.comDyne Therapeutics Elects Brian Posner to BoardOctober 2, 2025 | tipranks.comDyne Therapeutics Appoints Brian Posner to Board of DirectorsOctober 2, 2025 | quiverquant.comQDyne Therapeutics Appoints Brian Posner to its Board of DirectorsOctober 2, 2025 | globenewswire.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Buy" from AnalystsOctober 1, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 7.2% - Here's WhySeptember 29, 2025 | marketbeat.comDyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular DystrophySeptember 29, 2025 | globenewswire.comVoya Investment Management LLC Sells 200,017 Shares of Dyne Therapeutics, Inc. $DYNSeptember 27, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Down 3.7% - What's Next?September 13, 2025 | marketbeat.comExploring Dyne Therapeutics (DYN) Valuation After Recent Share Price ReboundSeptember 13, 2025 | finance.yahoo.com59,673 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Voleon Capital Management LPSeptember 12, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 2,640 SharesSeptember 11, 2025 | marketbeat.comExome Asset Management LLC Invests $2.70 Million in Dyne Therapeutics, Inc. $DYNSeptember 11, 2025 | marketbeat.comRaymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy RatingSeptember 10, 2025 | insidermonkey.comDyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.com62,269 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Graham Capital Management L.P.September 8, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comInvesco Ltd. Increases Position in Dyne Therapeutics, Inc. $DYNSeptember 7, 2025 | marketbeat.comTrexquant Investment LP Has $3.50 Million Holdings in Dyne Therapeutics, Inc. $DYNSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Invests $315,000 in Dyne Therapeutics, Inc. $DYNSeptember 4, 2025 | marketbeat.com1,800,000 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Acquires 3,333,248 Shares of Dyne Therapeutics, Inc. $DYNSeptember 4, 2025 | marketbeat.com1,443,341 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Frazier Life Sciences Management L.P.September 4, 2025 | marketbeat.com333,391 Shares in Dyne Therapeutics, Inc. $DYN Acquired by Palo Alto Investors LPSeptember 4, 2025 | marketbeat.com224,176 Shares in Dyne Therapeutics, Inc. $DYN Purchased by PDT Partners LLCSeptember 4, 2025 | marketbeat.comDyne Therapeutics, Inc. $DYN Shares Acquired by Braidwell LPSeptember 3, 2025 | marketbeat.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼1.160.49▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼138▲DYN Articles Average Week Get the Latest News and Ratings for DYN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Abivax News Today Avidity Biosciences News Today Cytokinetics News Today Merus News Today Rhythm Pharmaceuticals News Today CRISPR Therapeutics News Today Grifols News Today Nuvalent News Today Axsome Therapeutics News Today Legend Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredGold surges past $4,200 … but this has beat gold by 1,000xGold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
